• Users Online: 513
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 11  |  Issue : 3  |  Page : 266-272

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab


Department of Ophthalmology, Alexandria University, Alexandria, Egypt

Correspondence Address:
Dr. Mahmoud Alaa Abouhussein
8 Hassan Allam Street, Smouha, Alexandria
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/tjo.tjo_85_20

Rights and Permissions

PURPOSE: The aim of this study is to evaluate the functional and anatomical effects of switching from bevacizumab to aflibercept in patients with persistent diabetic macular edema (DME) resistant to bevacizumab. MATERIALS AND METHODS: Patients with DME refractory to bevacizumab (1.25 mg/0.05 mL) were subsequently switched to aflibercept. The included patients received five loading doses of intravitreal aflibercept (2 mg/0.05 mL) given monthly. After the loading dose, aflibercept was injected every 2 months. The follow-up duration was 1 year. RESULTS: The study consisted of 37 eyes of 37 patients. The mean age of the participants was 56.81 ± 7.11 years. The mean central macular thickness at baseline was 428.32 ± 84.89 μm, which decreased significantly to 275.54 ± 50.24 μm (P < 0.003). There was a significant improvement in the mean best-corrected logMAR visual acuity from 0.627 ± 0.307 at baseline to 0.203 ± 0.235 (P < 0.017) at the end of follow-up. CONCLUSIONS: Aflibercept is effective in patients with persistent DME not responsive to bevacizumab.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed651    
    Printed19    
    Emailed0    
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal